US 12,291,556 B2
Parathyroid hormone variants
Clark Pan, Sudbury, MA (US); Angela Norton, Reading, MA (US); Kevin Holmes, Belmont, MA (US); David Lloyd, Leland, NC (US); Bryan Goodwin, Lexington, MA (US); Rongxin Shi, Waltham, MA (US); Sujit Jain, Lexington, MA (US); and Chuan Shen, West Roxbury, MA (US)
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed by TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed on Mar. 2, 2023, as Appl. No. 18/116,766.
Application 18/116,766 is a continuation of application No. 16/776,107, filed on Jan. 29, 2020, granted, now 11,634,468.
Claims priority of provisional application 62/884,730, filed on Aug. 9, 2019.
Claims priority of provisional application 62/800,744, filed on Feb. 4, 2019.
Claims priority of provisional application 62/798,113, filed on Jan. 29, 2019.
Prior Publication US 2023/0340057 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/635 (2006.01); A61K 9/00 (2006.01); A61P 5/18 (2006.01); C07K 1/16 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/635 (2013.01) [A61K 9/0014 (2013.01); A61P 5/18 (2018.01); C07K 1/165 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)] 17 Claims
 
1. A method of increasing serum calcium levels in a subject in need thereof comprising administering to the subject an effective amount of a parathyroid hormone (PTH)-Fc fusion protein, wherein the PTH-Fc fusion protein is PTH-66 having the amino acid sequence of SEQ ID NO: 8.